SARS-CoV-2 infection in patients with autoimmune rheumatic diseases in northeast Italy: A cross-sectional study on 916 patients.
ANCA vasculitis
Idiopathic inflammatory myopathies
Rheumatoid arthritis
SARS-CoV-2
Systemic lupus erythematosus
Systemic sclerosis
Journal
Journal of autoimmunity
ISSN: 1095-9157
Titre abrégé: J Autoimmun
Pays: England
ID NLM: 8812164
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
13
05
2020
revised:
01
06
2020
accepted:
04
06
2020
pubmed:
13
6
2020
medline:
4
8
2020
entrez:
13
6
2020
Statut:
ppublish
Résumé
Whether patients with autoimmune rheumatic diseases (ARD) have a higher risk for SARS-CoV-2 infection (COVID-19) and how SARS-CoV-2 pandemic impacts on adherence to therapy has not been fully elucidated. We assessed the rate and clinical presentation of COVID-19, and adherence to therapy in a large cohort of patients with ARD followed-up in a tertiary University-Hospital in Northeast Italy. Between April 9th and April 25th 916 patients (397 SLE, 182 AAV, 176 SSc, 111 RA, 50 IIM) completed the survey. 148 patients developed at least one symptom compatible with COVID-19 (cough 96, sore throat 64, fever 64, arthromyalgias 59, diarrhea 26, conjunctivitis 18, ageusia/hyposmia, 18). Among the 916 patients, 65 (7.1%) underwent SARS-CoV-2 nasopharyngeal swab (18 symptomatic and 47 asymptomatic), 2 (0.21%) tested positive, a proportion similar to that observed in the general population of the Veneto region. No deaths occurred. 31 patients (3.4%) withdrew ≥1 medication, mainly immunosuppressants or biologics. Adoption of social distancing was observed by 860 patients (93.9%), including 335 (36.6%) who adopted it before official lockdown. COVID-19 incidence seems to be similar in our cohort compared to the general population. Adherence to therapy and to social distancing advise was high.
Sections du résumé
BACKGROUND
Whether patients with autoimmune rheumatic diseases (ARD) have a higher risk for SARS-CoV-2 infection (COVID-19) and how SARS-CoV-2 pandemic impacts on adherence to therapy has not been fully elucidated. We assessed the rate and clinical presentation of COVID-19, and adherence to therapy in a large cohort of patients with ARD followed-up in a tertiary University-Hospital in Northeast Italy.
METHODS
Between April 9th and April 25th
RESULTS
916 patients (397 SLE, 182 AAV, 176 SSc, 111 RA, 50 IIM) completed the survey. 148 patients developed at least one symptom compatible with COVID-19 (cough 96, sore throat 64, fever 64, arthromyalgias 59, diarrhea 26, conjunctivitis 18, ageusia/hyposmia, 18). Among the 916 patients, 65 (7.1%) underwent SARS-CoV-2 nasopharyngeal swab (18 symptomatic and 47 asymptomatic), 2 (0.21%) tested positive, a proportion similar to that observed in the general population of the Veneto region. No deaths occurred. 31 patients (3.4%) withdrew ≥1 medication, mainly immunosuppressants or biologics. Adoption of social distancing was observed by 860 patients (93.9%), including 335 (36.6%) who adopted it before official lockdown.
CONCLUSIONS
COVID-19 incidence seems to be similar in our cohort compared to the general population. Adherence to therapy and to social distancing advise was high.
Identifiants
pubmed: 32527675
pii: S0896-8411(20)30124-4
doi: 10.1016/j.jaut.2020.102502
pmc: PMC7832807
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
102502Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest All Authors declare they have no competing interests to report.
Références
Data Brief. 2020 Apr 10;30:105526
pubmed: 32346568
Lancet Rheumatol. 2020 May;2(5):e250-e253
pubmed: 32309814
Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S12-7
pubmed: 18570749
Ann Rheum Dis. 2020 Jun;79(6):737-739
pubmed: 32295789
J Leukoc Biol. 2010 Mar;87(3):385-95
pubmed: 20015961
Exp Biol Med (Maywood). 2020 Jun;245(11):970-976
pubmed: 32460624
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Ann Rheum Dis. 2021 Jan;80(1):e1
pubmed: 32299795
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Ann Rheum Dis. 2021 Feb;80(2):e18
pubmed: 32321723
Ann Rheum Dis. 2020 Jun;79(6):837-839
pubmed: 32332072